|
WO2020170231A1
|
|
Methods for identifying and improving t cell multipotency
|
|
WO2018009506A1
|
|
Erythroid-specific promoter and method of use thereof
|
|
WO2017156057A1
|
|
Retroviral construct harboring a let-7 insensitive nucleic acid encoding hmga2 and methods of use thereof
|
|
WO2016205806A1
|
|
Methods and compositions for the prevention and treatment of hearing loss
|
|
WO2016196478A1
|
|
Methods and compositions for prognostications and/or clinical management of graft-versus-host disease and transplant rejection
|
|
WO2016141351A1
|
|
Substituted urea depsipeptide analogs as activators of the clpp endopeptidase
|
|
US2015157696A1
|
|
Composition and method for inhibiting tumor cell growth
|
|
US2016003797A1
|
|
Method for detection of adenosine and metabolites thereof
|
|
US2016009728A1
|
|
Anticancer compounds
|
|
US2015266959A1
|
|
Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
|
|
US2015133462A1
|
|
Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
|
